[
    {
        "example_id": 106,
        "problem": [
            "Imagine a situation where a novel natural molecule, Xantheraquin, is discovered and is being investigated for in silico testing against a bacterial pathogen that is multidrug resistant. Preliminary studies indicate that Xantheraquin has multiple chiral centers and can exist in various tautomeric forms. Which of the following steps would be the MOST crucial before proceeding with in silico docking studies, given the complexities of bioinformatics in structure-based drug discovery, ?",
            "Use the most stable chiral form of Xantheraquin, relying on quantum mechanical calculations to predict its interaction with the bacterial target.",
            "Combine in silico predictions with preliminary in vitro binding affinity assays to validate the most promising forms of Xantheraquin before extensive docking studies.",
            "Analyze all tautomeric and chiral forms, but prioritize those forms that are most likely to be biologically active based on physicochemical properties.",
            "Focus on Xantheraquin's pharmacokinetics and ADME (Absorption, Distribution, Metabolism, Excretion) properties, using molecular dynamics simulations to predict its behavior in a biological system.",
            1
        ],
        "correct_answer": 1,
        "n": "abstracted_workflow_0_106",
        "response": "To accurately predict ADME and pharmacokinetics via MD, we must model realistic protonation/tautomer states, solvation, and membrane environments. Key missing data include precise pKa values, tautomeric distributions, logP/logD, solubility, and stereochemically defined structures. Without these, simulation inputs will be unreliable.\n\nAnswer:1. Prepare all relevant protonation and tautomeric states of Xantheraquin at physiological pH, using pKa predictions.\n2. Parameterize each form with a validated force field (e.g., CHARMM or AMBER); generate high-quality 3D coordinates.\n3. Set up explicit solvent MD simulations to estimate aqueous solubility and diffusion coefficients.\n4. Build membrane models representative of bacterial and mammalian cell membranes; run MD to assess passive permeability and bilayer partitioning.\n5. Use free\u2010energy perturbation or umbrella\u2010sampling methods to calculate binding affinities to serum proteins and membrane translocation barriers.\n6. Post-process trajectories to derive ADME\u2010relevant metrics: logP/logD, permeability coefficients, volume of distribution, and predicted clearance rates.\n[TOO_HARD]\nPlease provide stereochemically annotated SMILES or 3D coordinates, experimental or predicted pKa values, solubility data, logP/logD estimates, and the desired membrane compositions to enable precise setup of the MD simulations.",
        "sub_tasks_text": null
    },
    {
        "example_id": 106,
        "problem": [
            "Imagine a situation where a novel natural molecule, Xantheraquin, is discovered and is being investigated for in silico testing against a bacterial pathogen that is multidrug resistant. Preliminary studies indicate that Xantheraquin has multiple chiral centers and can exist in various tautomeric forms. Which of the following steps would be the MOST crucial before proceeding with in silico docking studies, given the complexities of bioinformatics in structure-based drug discovery, ?",
            "Use the most stable chiral form of Xantheraquin, relying on quantum mechanical calculations to predict its interaction with the bacterial target.",
            "Combine in silico predictions with preliminary in vitro binding affinity assays to validate the most promising forms of Xantheraquin before extensive docking studies.",
            "Analyze all tautomeric and chiral forms, but prioritize those forms that are most likely to be biologically active based on physicochemical properties.",
            "Focus on Xantheraquin's pharmacokinetics and ADME (Absorption, Distribution, Metabolism, Excretion) properties, using molecular dynamics simulations to predict its behavior in a biological system.",
            1
        ],
        "correct_answer": 1,
        "n": "abstracted_workflow_3_106",
        "response": "To rank the chiral/tautomeric forms of Xantheraquin accurately, both quantitative in silico docking scores and in vitro binding constants are essential. Without these values, one can only outline the workflow but cannot finalize the selection. Hence, this task is currently infeasible without additional data.\n\nAnswer:1. Compile in silico docking scores (e.g., GlideScore, AutoDock Vina) for each chiral/tautomeric form of Xantheraquin.\n2. Gather in vitro binding data from SPR (kon, koff, KD) and ITC (\u0394H, \u0394S, KD) for the same forms.\n3. Normalize and weight the in silico and in vitro metrics to compute a composite ranking score for each form.\n4. Rank all forms by the composite score and select the top 2\u20133 candidates for extensive docking studies.\n[TOO_HARD]\nPlease provide the detailed docking scores and corresponding SPR/ITC binding constants for each chiral/tautomeric form so that we can calculate the composite ranking and finalize the selection.",
        "sub_tasks_text": null
    }
]